MedTrace Logo

Mesenchymal Stem Cells for the Treatment of COVID-19

NCT04573270 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-10-05

No results posted yet for this study

Summary

This double blind, placebo controlled, multi-arm, multi-site study investigates the safety and efficacy of stem cell therapy for the treatment of patients admitted to hospital suffering complications from COVID-19 and the treatment of healthy subjects (healthcare providers) for prophylactic effect following those patients.

Conditions

  • Covid19
  • Prophylaxis

Interventions

BIOLOGICAL

PrimePro

Intravenous Injection

OTHER

Placebo

Intravenous Injection

Sponsors & Collaborators

  • HeartStem Institute

    collaborator UNKNOWN

  • Thomas Advanced Medical LLC

    lead INDUSTRY

Principal Investigators

  • Ernst R Von Schwarz, MD, PhD · HeartStem Institute, Southern California Hospital at Culver City

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-24
Primary Completion
2020-08-20
Completion
2020-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04573270 on ClinicalTrials.gov